- Home
- COCH vs LTRN Comparison
COCH vs LTRN Comparison
Compare COCH & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- LTRN
- Stock Information
- Founded
- COCH 1995
- LTRN 2013
- Country
- COCH United States
- LTRN United States
- Employees
- COCH N/A
- LTRN N/A
- Industry
- COCH Blank Checks
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- LTRN Health Care
- Exchange
- COCH Nasdaq
- LTRN Nasdaq
- Market Cap
- COCH 31.6M
- LTRN 36.0M
- IPO Year
- COCH N/A
- LTRN 2020
- Fundamental
- Price
- COCH $1.62
- LTRN $4.02
- Analyst Decision
- COCH Strong Buy
- LTRN Strong Buy
- Analyst Count
- COCH 2
- LTRN 1
- Target Price
- COCH $9.25
- LTRN $25.00
- AVG Volume (30 Days)
- COCH 30.6K
- LTRN 312.5K
- Earning Date
- COCH 08-11-2025
- LTRN 08-07-2025
- Dividend Yield
- COCH N/A
- LTRN N/A
- EPS Growth
- COCH N/A
- LTRN N/A
- EPS
- COCH N/A
- LTRN N/A
- Revenue
- COCH $212,000.00
- LTRN N/A
- Revenue This Year
- COCH $5.93
- LTRN N/A
- Revenue Next Year
- COCH $17.69
- LTRN N/A
- P/E Ratio
- COCH N/A
- LTRN N/A
- Revenue Growth
- COCH N/A
- LTRN N/A
- 52 Week Low
- COCH $1.21
- LTRN $2.55
- 52 Week High
- COCH $3.99
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- COCH 58.19
- LTRN 67.20
- Support Level
- COCH $1.56
- LTRN $3.15
- Resistance Level
- COCH $1.80
- LTRN $4.43
- Average True Range (ATR)
- COCH 0.12
- LTRN 0.38
- MACD
- COCH 0.02
- LTRN 0.11
- Stochastic Oscillator
- COCH 60.00
- LTRN 80.91
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.